Asset profile

cabozantinib · Exelixis (EXEL)

Indication: previously treated advanced neuroendocrine tumors (NET)
Also known as: CABOMETYX

Company

Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the tre…

Start live analysis of EXEL Run 8-agent AI analysis

On the calendar

May 2026

May 29, 2026

155 days ago

EXELExelixis

Exelixis: CABINET subgroup data at ASCO 2026 show cabozantinib PFS benefit in NET

Conference presentationOutcome not recordedCompany press release

Timeline

Newest first.

May 30, 2026

02:00 PM

EXELExelixis

Exelixis: CABINET subgroup data at ASCO 2026 show cabozantinib PFS benefit in NET

Conference presentationCompany press release

Readiness checklist

Public facts only. We never publish an approval probability.

Updated Sep 16, 2026

Primary endpoint metUnknown

Overall survival significant or trendingUnknown

US / Western patient shareFavourable

952 of 1276 sites in the United States

Advisory committee scheduledFavourable

No advisory committee announced

PDUFA date extendedUnknown

Manufacturing inspection recordUnknown

No public inspection record

Company language signals (label discussions)Unknown

Same-class precedentUnknown

Related companies

Each relationship is backed by the filing that stated it.

Ipsen Pharma SAS Not US-listedPartner

EXELExelixisOwner

Company press release May 30, 2026

TAKTakedaPartner

Company press release May 30, 2026

Verify every date against the linked primary source. Informational only. Not investment advice. SimianX is not affiliated with the FDA or the SEC.

Registered trials

Registry ID	Phase	Status	Primary completion	Enrollment	Sites
NCT02761057	Phase 2	Completed	Oct 19, 2023	152	586 of 595 sites in the United States
NCT01703065	Phase 2	Terminated	Feb 2, 2015	9	1 of 1 sites in the United States
NCT00940225	Phase 2	Completed	May 1, 2013	730	34 of 47 sites in the United States
NCT01738438	Phase 2	Completed	May 1, 2015	35	3 of 3 sites in the United States
NCT05007613	Phase 2	Completed	Jul 17, 2024	24	0 of 1 sites in the United States
NCT04471428	Phase 3	Completed	Sep 28, 2022	366	12 of 92 sites in the United States
NCT03367741	Phase 2	Active, not recruiting	May 9, 2025	82	33 of 34 sites in the United States
NCT01716715	Phase 2	Completed	Mar 16, 2015	111	173 of 173 sites in the United States
NCT01605227	Phase 3	Completed	Sep 1, 2014	1028	77 of 264 sites in the United States
NCT04524208	Phase 2	Unknown	Sep 30, 2024	45	0 of 15 sites in the United States
NCT06377722	Phase 2	Terminated	Aug 9, 2022	18	0 of 8 sites in the United States
NCT03425201	Phase 1/2	Completed	Jul 31, 2024	67	0 of 10 sites in the United States
NCT03914300	Phase 2	Active, not recruiting	Oct 17, 2024	11	33 of 33 sites in the United States

More from Exelixis

Other drugs and candidates from the same company tracked in this sector.

zanzalintinibpreviously treated metastatic colorectal cancer (CRC)